AstraZeneca enters obesity market with $2b deal for GLP-1 candidate
AstraZeneca has signed an exclusive license agreement with Shanghai-based biotech Eccogene for ECC5004, an early-stage investigational...
top of page
Browse by category
Search
Lilly's Mounjaro (tirzepatide) receives UK marketing authorisation for weight management
Eli Lilly and Company has granted marketing authorisation (MA) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for...
Low risk of bowel resection is low in patients presenting with small bowel obstruction post-RYGB
The overall risk of bowel resection is low in patients having small bowel obstruction after Roux-en-Y gastric bypass (RYGB) and the risk...
Activating pathway promotes population of insulin-producing cells and enhances cells' function
Researchers at Weill Cornell Medicine have uncovered a novel route to stimulate the growth of healthy insulin-producing pancreatic beta...
FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management
The FDA has approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that...
Journal Watch 8/11/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Browse by tag
bottom of page